News | December 02, 2023
USFDA inspection at Alkem Laboratories API manufacturing facility located at Mandva
The company has received Form 483 with three observations
The company has received Form 483 with three observations
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
The initiative will focus on advocating for cleaner air
Education on Inhalation Therapy & Conducting Nationwide Awareness Camps, Alkem Breathe Initiative Addresses the Alarming Increase in Respiratory Diseases in India
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
The company has reported total income of Rs. 2971.27 crores during the period ended March 31, 2023
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
Zidavi is recommended by the Infectious Disease Society of America
Subscribe To Our Newsletter & Stay Updated
